Medication use and associated health care outcomes and costs for patients with psoriasis in the United States

Journal of Dermatological Treatment

Volumn 23, Issue 3, 2012, Pages 196-202

  Lin, Hsien Chang ^a   Lucas, Pedro T ^b   Feldman, Steven R ^c   Balkrishnan, Rajesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF LISBON   (Portugal)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Costs; Outcomes; Pharmacology; Psoriasis; Quality of life; United States

Indexed keywords

ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPENDITURE PANEL SURVEY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; UNITED STATES;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL AGENTS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DERMATOLOGIC AGENTS; DRUG COSTS; DRUG UTILIZATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHOTOTHERAPY; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 84861039753     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.544708     Document Type: Article

References (48)

1. About Psoriasis - Statistics [Internet]. Portland, OR: National Psoriasis Foundation [cited 2010 February 28]. Available from: http://www.psoriasis.org/ netcommunity/learn-statistics.
2. Psoriasis [Internet]. Bethesda, MD: National Institute of Arthritis and Musculoskeletal and Skin, National Institute of Health [cited 2010 February 28]. Available from: http://www.niams.nih.gov.proxy.lib.umich.edu/Health-Info/ Psoriasis/default.asp.
3. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. J Am Acad Dermatol. 2009; 60 (2): 218-224.
4. Treatment of Psoriasis [Internet]. Waltham, MA: UpToDate [cited 2010 March 07]. Available from: http://www.uptodate. com/online/content/topic.do? topicKey=papulos/5539&selected Title=1~150&source=search-result.
5. Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatol Clin. 2004; 22 (4): 389.
6. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008; 59 (5): 772-780.
7. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006; 213 (2): 102-110. (Pubitemid 44215193)
8. Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008; 26 (5): 424-431.
9. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002; 46 (6): 850-860.
10. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004; 20 (12): 1929-1936. (Pubitemid 40179632)
11. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009; 25 (10): 2429-2438.
12. Finzi AF, Mantovani LG, Belisari A; Italian Association for Studies on Psoriasis. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol. 2001; 15 (4): 320-324. (Pubitemid 33014842)
13. Melnikova I. Psoriasis market. Nat Rev Drug Discov. 2009; 8 (10): 767-768.
14. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000; 25 (1): 1-10. (Pubitemid 30175546)
15. Callen JP, Krueger GG, LebwohlM,McBurney EI, Mease P, Menter A, et al.; AAD. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003; 49 (5): 897-899. (Pubitemid 37314880)
16. Baughman RD. A 61-year-old man with psoriasis. JAMA. 1996; 276 (17): 1421-1428. (Pubitemid 26365849)
17. Nast A, Erdmann R, Pathirana D, Rzany B. Translating psoriasis treatment guidelines into clinical practice - the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract. 2008; 14 (5): 803-806.
18. Strowd LC, Yentzer BA, Fleischer AB Jr, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009; 60 (3): 478-481.
19. Nast A, Spuls PH, Ormerod AD, Reytan N, Saiag PH, Smith CH, et al. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: 'AGREE-ing' on acommon base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol. 2009; 23 (7): 782-787.
20. Lebwohl M. Psoriasis. Lancet. 2003; 361 (9364): 1197-1204.
21. Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: Traditional therapy. Ann Rheum Dis. 2005; 64 (suppl 2): ii83-86. (Pubitemid 40288530)
22. Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR. Psoriasis treatment in the united states at the end of the 20th century. Int J Dermatol. 2006; 45 (4): 370-374.
23. Schon MP. Advances in psoriasis treatment. Lancet. 2005; 366 (9494): 1333-1335. (Pubitemid 41443387)
24. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al.; International Psoriasis Council. Psoriasis: Improving adherence to topical therapy. J AmAcad Dermatol. 2008; 59 (6): 1009-1016.
25. Patel V, Horn EJ, Lobosco SJ, Fox KM, Stevens SR, Lebwohl M. Psoriasis treatment patterns: Results of across-sectional survey of dermatologists. J Am Acad Dermatol. 2008; 58 (6): 964-969.
26. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: Current and emerging directed therapies. Ann Rheum Dis. 2005; 64 (suppl 2): ii87.
27. Report on the Psycho-Social Impacts of Psoriasis [Internet]. Portland, OR: National Psoriasis Foundation [cited 2010 February 28]. Available from: http://www.psoriasis.org/Net Community/Document.Doc?id=619.
28. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6 (6): 383-392. (Pubitemid 43128290)
29. De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc. 2004; 9 (2): 140-147. (Pubitemid 38457272)
30. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006; 4: 35.
31. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: A critical appraisal of their quality. J Clin Pharm Ther. 1998; 23 (5): 391-398. (Pubitemid 28566870)
32. Mckenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol. 1996; 34 (3): 534-538. (Pubitemid 26083843)
33. Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol. 2005; 52 (1): 27-31. (Pubitemid 40038932)
34. Benoit S, Hamm H. Childhood psoriasis. Clin Dermatol. 2007; 25 (6): 555-562. (Pubitemid 350087602)
35. Burden AD. Management of psoriasis in childhood. Clin Exp Dermatol. 1999; 24 (5): 341-345. (Pubitemid 29491200)
36. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45 (6): 613-619.
37. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996; 49 (12): 1429-1433. (Pubitemid 27028932)
38. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther. 2003; 25 (11): 2958-2971. (Pubitemid 37510603)
39. Lee ES, Forthofer RN, Lorimor RJ. Analysis of complex sample survey data: Problems and strategies. Sociological Methods Research. 1986; 15 (1-2): 69.
40. Aparasu RR. Autonomous ambulatory care by nurse practitioners and physician assistants in office-based settings. J Allied Health. 2001; 30 (3): 153-159. (Pubitemid 33759719)
41. Goodwin R, Gould MS, Blanco C, Olfson M. Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv. 2001; 52 (8): 1081-1087. (Pubitemid 32758001)
42. Sobal J, Rauschenbach B, Frongillo EA. Marital status changes and body weight changes: A US longitudinal analysis. Soc Sci Med. 2003; 56 (7): 1543-1555. (Pubitemid 36279487)
43. Sleath B, Tina Shih Y. Sociological influences on antidepressant prescribing. Soc Sci Med. 2003; 56 (6): 1335-1344. (Pubitemid 36216330)
44. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40 (5): 373-383. (Pubitemid 17055592)
45. Van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998; 197 (1): 31-36. (Pubitemid 28327834)
46. Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: A personal appraisal of their use in practice. J Am Acad Dermatol. 2003; 49 (2): 351-356. (Pubitemid 36951300)
47. Kupper TS. Immunologic targets in psoriasis. N Engl J Med. 2003; 349 (21): 1987-1990. (Pubitemid 37448920)
48. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol. 2006; 33 (7): 1447-1451. (Pubitemid 44025168)